208 related articles for article (PubMed ID: 31188522)
41. Birth defects in a cohort of infants born to HIV-infected women in Spain, 2000-2009.
Prieto LM; González-Tomé MI; Muñoz E; Fernández-Ibieta M; Soto B; Álvarez A; Navarro ML; Roa MÁ; Beceiro J; de José MI; Olabarrieta I; Lora D; Ramos JT;
BMC Infect Dis; 2014 Dec; 14():700. PubMed ID: 25808698
[TBL] [Abstract][Full Text] [Related]
42. Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1.
Pinnetti C; Tintoni M; Ammassari A; Tamburrini E; Bernardi S; Liuzzi G; Scambia G; Perno CF; Floridia M; Antinori A; Cavaliere AF
AIDS; 2015 Nov; 29(18):2534-7. PubMed ID: 26372490
[No Abstract] [Full Text] [Related]
43. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis.
Uthman OA; Nachega JB; Anderson J; Kanters S; Mills EJ; Renaud F; Essajee S; Doherty MC; Mofenson LM
Lancet HIV; 2017 Jan; 4(1):e21-e30. PubMed ID: 27864000
[TBL] [Abstract][Full Text] [Related]
44. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern?
Thorne C; Newell ML
Drug Saf; 2007; 30(3):203-13. PubMed ID: 17343429
[TBL] [Abstract][Full Text] [Related]
45. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
Ochanda PN; Lamorde M; Kintu K; Wang D; Chen T; Malaba T; Myer L; Waitt C; Reynolds H; Khoo S
AIDS Res Ther; 2022 Jun; 19(1):24. PubMed ID: 35672853
[TBL] [Abstract][Full Text] [Related]
46. Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland.
Tookey PA; Thorne C; van Wyk J; Norton M
BMC Infect Dis; 2016 Feb; 16():65. PubMed ID: 26847625
[TBL] [Abstract][Full Text] [Related]
47. Safety of in-utero antiretroviral exposure: neurologic outcomes in children who are HIV-exposed but uninfected.
Crowell CS; Williams PL; Yildirim C; Van Dyke RB; Smith R; Chadwick EG; Seage GR; Diperna A; Hazra R;
AIDS; 2020 Jul; 34(9):1377-1387. PubMed ID: 32310900
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness of community-based support for pregnant women living with HIV: a cohort study in South Africa.
Fatti G; Shaikh N; Eley B; Grimwood A
AIDS Care; 2016; 28 Suppl 1(sup1):114-8. PubMed ID: 26922939
[TBL] [Abstract][Full Text] [Related]
49. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception.
Mandelbrot L; Tubiana R; Le Chenadec J; Dollfus C; Faye A; Pannier E; Matheron S; Khuong MA; Garrait V; Reliquet V; Devidas A; Berrebi A; Allisy C; Elleau C; Arvieux C; Rouzioux C; Warszawski J; Blanche S;
Clin Infect Dis; 2015 Dec; 61(11):1715-25. PubMed ID: 26197844
[TBL] [Abstract][Full Text] [Related]
50. Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use.
Crawford M; van Wyk J; Aboud M; Vannappagari V; Romach B; Curtis L; Wynne B; de Ruiter A; Smith K; Payvandi N
J Acquir Immune Defic Syndr; 2020 Jan; 83(1):e2-e5. PubMed ID: 31809366
[No Abstract] [Full Text] [Related]
51. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.
Ford N; Mofenson L; Shubber Z; Calmy A; Andrieux-Meyer I; Vitoria M; Shaffer N; Renaud F
AIDS; 2014 Mar; 28 Suppl 2():S123-31. PubMed ID: 24849471
[TBL] [Abstract][Full Text] [Related]
52. Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda.
Mbabazi L; Nabaggala MS; Kiwanuka S; Kiguli J; Laker E; Kiconco A; Okoboi S; Lamorde M; Castelnuovo B
BMC Womens Health; 2022 Jun; 22(1):262. PubMed ID: 35761248
[TBL] [Abstract][Full Text] [Related]
53. National-level effectiveness of ART to prevent early mother to child transmission of HIV in Namibia.
Agabu A; Baughman AL; Fischer-Walker C; de Klerk M; Mutenda N; Rusberg F; Diergaardt D; Pentikainen N; Sawadogo S; Agolory S; Dinh TH
PLoS One; 2020; 15(11):e0233341. PubMed ID: 33170840
[TBL] [Abstract][Full Text] [Related]
54. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
55. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
[TBL] [Abstract][Full Text] [Related]
56. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
[TBL] [Abstract][Full Text] [Related]
57. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis.
Allen Reeves A; Fuentes AV; Caballero J; Thomas JE; Mosley Ii JF; Harrington C
Sex Transm Infect; 2021 Jun; 97(4):261-267. PubMed ID: 33782144
[TBL] [Abstract][Full Text] [Related]
58. Dolutegravir Use at Conception - Additional Surveillance Data from Botswana.
Raesima MM; Ogbuabo CM; Thomas V; Forhan SE; Gokatweng G; Dintwa E; Petlo C; Motswere-Chirwa C; Rabold EM; Tinker SC; Odunsi S; Malima S; Mmunyane O; Modise T; Kefitlhile K; Dare K; Letebele M; Roland ME; Moore CA; Modi S; Williamson DM
N Engl J Med; 2019 Aug; 381(9):885-887. PubMed ID: 31329378
[No Abstract] [Full Text] [Related]
59. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
60. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011.
Floridia M; Mastroiacovo P; Tamburrini E; Tibaldi C; Todros T; Crepaldi A; Sansone M; Fiscon M; Liuzzi G; Guerra B; Vimercati A; Vichi F; Vicini I; Pinnetti C; Marconi AM; Ravizza M;
BJOG; 2013 Nov; 120(12):1466-75. PubMed ID: 23721372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
